Publications by authors named "Thomas Schiller"
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Connie A Haley Marcos C Schechter David Ashkin Charles A Peloquin J Peter Cegielski Thomas M Schiller
Clin Infect Dis
October 2023
Article Synopsis
- Rifampin-resistant tuberculosis is a major global health issue, with treatment initiation rates low and often poor outcomes; a 6-month BPaL regimen shows high efficacy but initial high doses of linezolid led to significant side effects.
- Data collected from patients treated with BPaL between October 2019 and April 2022 revealed that 97.1% completed treatment, with only a small percentage experiencing relapse or significant adverse effects, largely due to careful dose adjustments of linezolid.
- The study concludes that the BPaL regimen, especially with individualized linezolid dosing and monitoring, has significantly improved treatment for rifampin-resistant tuberculosis, allowing for shorter treatment durations compared to past guidelines.
To predict the coherence in local responses to large-scale climatic forcing among aquatic systems, we developed a generalized approach to compare long-term data of dimictic water bodies based on phenomenologically defined hydrographic events. These climate-sensitive phases (inverse stratification, spring overturn, early thermal stratification, summer stagnation) were classified in a dual code (cold/warm) based on threshold temperatures. Accounting for a latitudinal gradient in seasonal timing of phases derived from gradients in cumulative irradiation (2.
View Article and Find Full Text PDF